个体化与常规卵巢刺激在体外受精中的比较:一项多中心、随机、对照、评估者盲法、3期非劣效性试验
ESTHER-1试验纳入1329例18-40岁体外受精女性,比较基于血清抗苗勒管激素(AMH)和体重个体化给药的促卵泡激素δ与常规促卵泡激素α。个体化促卵泡激素δ的持续妊娠率、持续种植率和活产率与常规促卵泡激素α相似,非劣效性成立,且目标反应者更多、卵巢过度刺激综合征预防措施更少。
要点
- 个体化促卵泡激素δ与常规促卵泡激素α的持续妊娠率、持续种植率和活产率相似,非劣效性成立。
- 个体化促卵泡激素δ组目标反应(8-14个卵母细胞)比例更高,卵巢反应不良和反应过度比例更低。
- 个体化促卵泡激素δ组预防卵巢过度刺激综合征的措施更少,促性腺激素用量更少。
核心结论
- 根据治疗前患者特征个体化给药优化体外受精卵巢反应,与常规卵巢刺激相比疗效相似且安全性改善。
研究设计与样本
- 随机、多中心、评估者盲法、非劣效性3期试验(ESTHER-1),纳入1329例18-40岁女性,在生殖医学诊所进行。
主要发现
- 个体化促卵泡激素δ组与常规促卵泡激素α组的持续妊娠率分别为30.7%和31.6%,差异-0.9%(95%CI -5.9%至4.1%)。
- 持续种植率分别为35.2%和35.8%,差异-0.6%(95%CI -6.1%至4.8%);活产率分别为29.8%和30.7%,差异-0.9%(95%CI -5.8%至4.0%)。
- 目标反应(8-14个卵母细胞)比例分别为43.3%和38.4%;AMH<15 pmol/L患者中反应不良(少于4个卵母细胞)比例分别为11.8%和17.9%。
- AMH≥15 pmol/L患者中反应过度(≥15或≥20个卵母细胞)比例分别为27.9%和35.1%、10.1%和15.6%;预防卵巢过度刺激综合征措施分别为2.3%和4.5%。
- 获卵数分别为10.0±5.6和10.4±6.5,囊胚数分别为3.3±2.8和3.5±3.2,促性腺激素用量分别为90.0±25.3 μg和103.7±33.6 μg。
关键数值与推荐
- 个体化促卵泡激素δ剂量:AMH<15 pmol/L者12 μg/d;AMH≥15 pmol/L者0.10-0.19 μg/kg/d,最大12 μg/d。
- 常规促卵泡激素α剂量:150 IU/d用5天,后续可调整剂量,最大450 IU/d。
- 主要结局为非劣效性,非劣效界值为-8.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy and safety of follitropin delta, a new human recombinant FSH with individualized dosing based on serum antimüllerian hormone (AMH) and body weight, with conventional follitropin alfa dosing for ovarian stimulation in women undergoing IVF. DESIGN: Randomized, multicenter, assessor-blinded, noninferiority trial (ESTHER-1). SETTING: Reproductive medicine clinics. PATIENT(S): A total of 1,329 women (aged 18-40 years). INTERVENTION(S): Follitropin delta (AMH <15 pmol/L: 12 μg/d; AMH ≥15 pmol/L: 0.10-0.19 μg/kg/d; maximum 12 μg/d), or follitropin alfa (150 IU/d for 5 days, potential subsequent dose adjustments; maximum 450 IU/d). MAIN OUTCOMES MEASURE(S): Ongoing pregnancy and ongoing implantation rates; noninferiority margins -8.0%. RESULT(S): Ongoing pregnancy (30.7% vs. 31.6%; difference -0.9% [95% confidence interval (CI) -5.9% to 4.1%]), ongoing implantation (35.2% vs. 35.8%; -0.6% [95% CI -6.1% to 4.8%]), and live birth (29.8% vs. 30.7%; -0.9% [95% CI -5.8% to 4.0%]) rates were similar for individualized follitropin delta and conventional follitropin alfa. Individualized follitropin delta resulted in more women with target response (8-14 oocytes) (43.3% vs. 38.4%), fewer poor responses (fewer than four oocytes in patients with AMH <15 pmol/L) (11.8% vs. 17.9%), fewer excessive responses (≥15 or ≥20 oocytes in patients with AMH ≥15 pmol/L) (27.9% vs. 35.1% and 10.1% vs. 15.6%, respectively), and fewer measures taken to prevent ovarian hyperstimulation syndrome (2.3% vs. 4.5%), despite similar oocyte yield (10.0 ± 5.6 vs. 10.4 ± 6.5) and similar blastocyst numbers (3.3 ± 2.8 vs. 3.5 ± 3.2), and less gonadotropin use (90.0 ± 25.3 vs. 103.7 ± 33.6 μg). CONCLUSION(S): Optimizing ovarian response in IVF by individualized dosing according to pretreatment patient characteristics results in similar efficacy and improved safety compared with conventional ovarian stimulation. CLINICAL TRIAL REGISTRATION NUMBER: NCT01956110.
引用
- Nyboe Andersen A, Nelson SM, Fauser BC, et al. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2016. PMID: 27912901. doi:10.1016/j.fertnstert.2016.10.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。